<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635310</url>
  </required_header>
  <id_info>
    <org_study_id>940211</org_study_id>
    <nct_id>NCT00635310</nct_id>
  </id_info>
  <brief_title>Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin</brief_title>
  <official_title>Safety Profiles of Percutaneous Liver Biopsy in Hemodialysis Patients With Chronic Hepatitis C Pre-treated With 1-Deamino-8- D-Arginine Vasopressin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous liver biopsy (PLB) is the gold standard for grading necroinflammation and
      staging fibrosis in patients with chronic viral hepatitis. Whether the use of
      1-deamino-8-D-arginine vasopressin (DDAVP) before PLBs in hemodialysis (HD) patients with
      chronic viral hepatitis has comparable safety profiles to those with normal renal function
      (NRF) has not been evaluated in prospective studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic viral hepatitis is common in dialysis patients, with the reported prevalence and
      annual incidence of 3-80% and 2.9%, respectively. Currently, percutaneous liver biopsy (PLB)
      remains the gold standard for grading necroinflammation and staging fibrosis in patients with
      liver diseases. In addition, liver histology can help clinicians determine the eligibility of
      renal transplantation, prognosis, and necessity of antiviral therapy in dialysis patients
      with chronic viral hepatitis. In chronic hepatitis patients with normal renal function (NRF),
      the risks of fatal and non-fatal hemorrhage after liver biopsies for non-malignant diseases
      were 0.04% and 0.16%, respectively. However, the relative risks of post-biopsy hemorrhage in
      CHC patients with end-stage renal disease to those with NRF remain disputed.

      Deamino-8-D-arginine vasopressin (DDAVP), a synthetic analogue of vasopressin, is a commonly
      used hemostatic agent to treat uremic bleeding by inducing the release of von Willebrand
      factor (vWF) and factor VIII from their storage sites in endothelial cells.Previous studies
      have shown that one dose of 0.3-0.4Î¼g/kg body weight DDAVP infusion for dialysis patients
      could normalize bleeding time (BT), and prevent surgical and renal biopsy bleeding.
      Nevertheless, two recent studies showed divergent liver biopsy-related bleeding complication
      rates (0% and 6%, respectively) in dialysis CHC patients pre-treated with DDAVP. Since most
      studies evaluating the safety of PLB in CHC patients with dialysis were small and
      retrospective in nature, and not controlled by the biopsy route, the type of biopsy needle,
      the use of ultrasound guidance, or the number of passes,further studies are urgently needed
      to solve this important issue. Thus, we aimed to conducted a large clinical trial to compare
      the safety profiles of PLB between CHC patients with hemodialysis (HD) who were pretreated
      with DDAVP and those with NRF by the same biopsy technique.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy-related serious hemorrhage rate by intention-to-treat (ITT) analysis</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biopsy-related serious hemorrhage rate by per-protocol (PP) analysis</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3520</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Chronic Hepatitis B</condition>
  <condition>Biopsy</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>HD patients with CHC or CHB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with hemodialysis (HD), pretreated with DDAVP 0.3 ug/kg body weight infusion 30-60 minutes before percutaneous liver biopsies (PLBs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ordinary patients with CHC or CHB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with normal renal function (NRF) receiving percutaneous liver biopsies (PLBs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous liver biopsy</intervention_name>
    <description>Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)</description>
    <arm_group_label>HD patients with CHC or CHB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous liver biopsy</intervention_name>
    <description>Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)</description>
    <arm_group_label>Ordinary patients with CHC or CHB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C (presence of anti-HCV and serum HCV RNA &gt; 6 months)

          -  Chronic hepatitis B (presence of HBsAg &gt; 6 months)

          -  Receiving regular hemodialysis or normal renal function (Creatinine &lt; 1.5 x ULN)

          -  Receiving percutaneous liver biopsy (PLB)

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV) co-infection

          -  Unwilling or contraindicated to receive percutaneous liver biopsy (PLB)

          -  Receiving liver biopsy without ultrasound (US) guidance or automatic cutting needles

          -  Did not receive 2 passes of liver biopsy

          -  Inadequate record of post-biopsy complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia-Horng Kao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chun-Jen Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming-Yang Lai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pei-Jer Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ding-Shinn Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Chao Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shih-Jer Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jou-Wei Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shih-I Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hung-Bin Tsai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Martin De Porres Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peir-Haur Hung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chiayi Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun-Herng Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen-Hua Liu, MD</last_name>
    <phone>+886-2-23123456</phone>
    <phone_ext>3572</phone_ext>
    <email>jacque_liu@mail2000.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiayi Christian Hospital</name>
      <address>
        <city>Chia-Yi</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peir-Haur Hung, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peir-Haur Hung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Martin De Porres Hospital</name>
      <address>
        <city>Chia-Yi</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hung-Bin Tsai, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hung-Bin Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Jer Hsu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shih-Jer Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jou-Wei Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shih-I Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun-Herng Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Chao Liang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cheng-Chao Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen-Hua Liu, MD</last_name>
      <phone>+886-2-23123456</phone>
      <phone_ext>3572</phone_ext>
      <email>jacque_liu@mail2000.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chen-Hua Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia-Horng Kao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Jen Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Yang Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pei-Jer Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ding-Shinn Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Liver biopsy</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>1-Deamino-8- D-Arginine Vasopressin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

